Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 309

1.

C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.

Zhuang D, Mannava S, Grachtchouk V, Tang WH, Patil S, Wawrzyniak JA, Berman AE, Giordano TJ, Prochownik EV, Soengas MS, Nikiforov MA.

Oncogene. 2008 Nov 6;27(52):6623-34. doi: 10.1038/onc.2008.258. Epub 2008 Aug 4.

2.

Abrogation of BRAFV600E-induced senescence by PI3K pathway activation contributes to melanomagenesis.

Vredeveld LC, Possik PA, Smit MA, Meissl K, Michaloglou C, Horlings HM, Ajouaou A, Kortman PC, Dankort D, McMahon M, Mooi WJ, Peeper DS.

Genes Dev. 2012 May 15;26(10):1055-69. doi: 10.1101/gad.187252.112. Epub 2012 May 1.

3.

Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.

Jalili A, Wagner C, Pashenkov M, Pathria G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G, Fisher DE, Ramaswamy S, Wagner SN.

J Natl Cancer Inst. 2012 Nov 7;104(21):1673-9. doi: 10.1093/jnci/djs373. Epub 2012 Sep 20.

4.

Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.

Petti C, Molla A, Vegetti C, Ferrone S, Anichini A, Sensi M.

Cancer Res. 2006 Jul 1;66(13):6503-11.

5.

Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.

Lidsky M, Antoun G, Speicher P, Adams B, Turley R, Augustine C, Tyler D, Ali-Osman F.

J Biol Chem. 2014 Oct 3;289(40):27714-26. doi: 10.1074/jbc.M113.532432. Epub 2014 Jul 25.

6.

Melanocytic nevus-like hyperplasia and melanoma in transgenic BRAFV600E mice.

Goel VK, Ibrahim N, Jiang G, Singhal M, Fee S, Flotte T, Westmoreland S, Haluska FS, Hinds PW, Haluska FG.

Oncogene. 2009 Jun 11;28(23):2289-98. doi: 10.1038/onc.2009.95. Epub 2009 Apr 27.

7.

MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence.

Tabor V, Bocci M, Alikhani N, Kuiper R, Larsson LG.

Cancer Res. 2014 Aug 15;74(16):4222-9. doi: 10.1158/0008-5472.CAN-13-3234. Epub 2014 Jun 16.

8.

KIT Suppresses BRAFV600E-Mutant Melanoma by Attenuating Oncogenic RAS/MAPK Signaling.

Neiswender JV, Kortum RL, Bourque C, Kasheta M, Zon LI, Morrison DK, Ceol CJ.

Cancer Res. 2017 Nov 1;77(21):5820-5830. doi: 10.1158/0008-5472.CAN-17-0473. Epub 2017 Sep 25.

PMID:
28947418
9.

Activation of forkhead box O transcription factors by oncogenic BRAF promotes p21cip1-dependent senescence.

de Keizer PL, Packer LM, Szypowska AA, Riedl-Polderman PE, van den Broek NJ, de Bruin A, Dansen TB, Marais R, Brenkman AB, Burgering BM.

Cancer Res. 2010 Nov 1;70(21):8526-36. doi: 10.1158/0008-5472.CAN-10-1563. Epub 2010 Oct 19.

10.

The role of BRAF mutation and p53 inactivation during transformation of a subpopulation of primary human melanocytes.

Yu H, McDaid R, Lee J, Possik P, Li L, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra M, Hammond R, Nathanson KL, Dalla Palma M, Herlyn M, Xu X.

Am J Pathol. 2009 Jun;174(6):2367-77. doi: 10.2353/ajpath.2009.081057. Epub 2009 Apr 23.

11.

PP2A-B56α controls oncogene-induced senescence in normal and tumor human melanocytic cells.

Mannava S, Omilian AR, Wawrzyniak JA, Fink EE, Zhuang D, Miecznikowski JC, Marshall JR, Soengas MS, Sears RC, Morrison CD, Nikiforov MA.

Oncogene. 2012 Mar 22;31(12):1484-92. doi: 10.1038/onc.2011.339. Epub 2011 Aug 8.

12.

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS.

Nature. 2010 Dec 16;468(7326):973-7. doi: 10.1038/nature09626. Epub 2010 Nov 24.

13.

BRAFE600-associated senescence-like cell cycle arrest of human naevi.

Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, Majoor DM, Shay JW, Mooi WJ, Peeper DS.

Nature. 2005 Aug 4;436(7051):720-4.

14.

BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.

Kakavand H, Walker E, Lum T, Wilmott JS, Selinger CI, Smith E, Saw RP, Yu B, Cooper WA, Long GV, O'Toole SA, Scolyer RA.

Histopathology. 2016 Oct;69(4):680-6. doi: 10.1111/his.12992. Epub 2016 Jun 15.

PMID:
27151331
15.

BRAFV600E cooperates with PI3K signaling, independent of AKT, to regulate melanoma cell proliferation.

Silva JM, Bulman C, McMahon M.

Mol Cancer Res. 2014 Mar;12(3):447-63. doi: 10.1158/1541-7786.MCR-13-0224-T. Epub 2014 Jan 14.

16.

NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.

Uguen A, Talagas M, Costa S, Samaison L, Paule L, Alavi Z, De Braekeleer M, Le Marechal C, Marcorelles P.

Diagn Pathol. 2015 Jul 25;10:121. doi: 10.1186/s13000-015-0359-0.

17.

Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.

Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, Haanen J, Blank C, Wesseling J, Willems SM, Zecchin D, Hobor S, Bajpe PK, Lieftink C, Mateus C, Vagner S, Grernrum W, Hofland I, Schlicker A, Wessels LF, Beijersbergen RL, Bardelli A, Di Nicolantonio F, Eggermont AM, Bernards R.

Nature. 2014 Apr 3;508(7494):118-22. doi: 10.1038/nature13121. Epub 2014 Mar 26.

18.

Dual inactivation of RB and p53 pathways in RAS-induced melanomas.

Bardeesy N, Bastian BC, Hezel A, Pinkel D, DePinho RA, Chin L.

Mol Cell Biol. 2001 Mar;21(6):2144-53.

19.

The relative contributions of the p53 and pRb pathways in oncogene-induced melanocyte senescence.

Haferkamp S, Tran SL, Becker TM, Scurr LL, Kefford RF, Rizos H.

Aging (Albany NY). 2009 May 16;1(6):542-56.

20.

Anti-oncogenic role of the endoplasmic reticulum differentially activated by mutations in the MAPK pathway.

Denoyelle C, Abou-Rjaily G, Bezrookove V, Verhaegen M, Johnson TM, Fullen DR, Pointer JN, Gruber SB, Su LD, Nikiforov MA, Kaufman RJ, Bastian BC, Soengas MS.

Nat Cell Biol. 2006 Oct;8(10):1053-63. Epub 2006 Sep 10. Erratum in: Nat Cell Biol. 2006 Nov;8(11):1309.

PMID:
16964246

Supplemental Content

Support Center